Jean-Michel Molina

Jean-Michel Molina publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Jean-Michel Molina sits on this spectrum.

Jean-Michel Molina D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Jean-Michel Molina sits on this spectrum.

Best Publications

• HLA-B*5701 Screening for Hypersensitivity to Abacavir

  Simon Mallal;Elizabeth Phillips;Giampiero Carosi;Jean-Michel Molina

  2179
  Citations

• On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

  Abstr Act;C. Capitant;B. Spire;G. Pialoux

  1905
  Citations

• No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.

  J.M. Molina;C. Delaugerre;J. Le Goff;B. Mela-Lima

  883
  Citations

• Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

  Paul E Sax;David Wohl;Michael T Yin;Frank Post

  754
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

  Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  713
  Citations

• Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

  Jean-Michel Molina;Jaime Andrade-Villanueva;Juan Echevarria;Ploenchan Chetchotisakd

  681
  Citations

• Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

  Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  666
  Citations

• Hematopoietic growth factors. Biology and clinical applications.

  J E Groopman;J M Molina;D T Scadden

  647
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

  Unknown

  632
  Citations

• Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): A phase 3 randomised double-blind active-controlled trial

  Jean Michel Molina;Pedro Cahn;Beatriz Grinsztejn;Adriano Lazzarin

  529
  Citations

• Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

  Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  517
  Citations

• Tenofovir-Related Nephrotoxicity in Human Immunodeficiency Virus-Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes Insipidus

  Alexandre Karras;Matthieu Lafaurie;André Furco;Anne Bourgarit

  478
  Citations

• Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

  Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  472
  Citations

• Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

  Edwin DeJesus;Jürgen K. Rockstroh;Keith Henry;Jean Michel Molina

  454
  Citations

• Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment

  Yves Levy;Christine Lacabaratz;Laurence Weiss;Jean-Paul Viard

  444
  Citations

• Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.

  Kenneth H Mayer;Kenneth H Mayer;Jean-Michel Molina;Melanie A Thompson;Peter L Anderson

  430
  Citations

• Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial.

  Jean-Michel Molina;Isabelle Charreau;Christian Chidiac;Gilles Pialoux

  429
  Citations

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

  Unknown

  428
  Citations

• Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

  Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  416
  Citations

• Prognostic Factors and Outcome of Human Herpesvirus 8–Associated Primary Effusion Lymphoma in Patients With AIDS

  Emmanuelle Boulanger;Laurence Gérard;Jean Gabarre;Jean-Michel Molina

  370
  Citations